302 related articles for article (PubMed ID: 31024562)
1. Chronic HIV-1 Infection Alters the Cellular Distribution of FcγRIIIa and the Functional Consequence of the FcγRIIIa-F158V Variant.
Phaahla NG; Lassaunière R; Da Costa Dias B; Waja Z; Martinson NA; Tiemessen CT
Front Immunol; 2019; 10():735. PubMed ID: 31024562
[TBL] [Abstract][Full Text] [Related]
2. Terminal Effector CD8 T Cells Defined by an IKZF2
Naluyima P; Lal KG; Costanzo MC; Kijak GH; Gonzalez VD; Blom K; Eller LA; Creegan M; Hong T; Kim D; Quinn TC; Björkström NK; Ljunggren HG; Serwadda D; Katabira ET; Sewankambo NK; Gray RH; Baeten JM; Michael NL; Wabwire-Mangen F; Robb ML; Bolton DL; Sandberg JK; Eller MA
J Immunol; 2019 Oct; 203(8):2210-2221. PubMed ID: 31519862
[TBL] [Abstract][Full Text] [Related]
3. FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.
Talathi SP; Shaikh NN; Pandey SS; Saxena VA; Mamulwar MS; Thakar MR
BMC Infect Dis; 2019 Dec; 19(1):1053. PubMed ID: 31842762
[TBL] [Abstract][Full Text] [Related]
4. Impaired natural killer cell-induced antibody-dependent cell-mediated cytotoxicity is associated with human immunodeficiency virus-1 disease progression.
Jia M; Li D; He X; Zhao Y; Peng H; Ma P; Hong K; Liang H; Shao Y
Clin Exp Immunol; 2013 Jan; 171(1):107-16. PubMed ID: 23199330
[TBL] [Abstract][Full Text] [Related]
5. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
8. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects.
Oboshi W; Watanabe T; Matsuyama Y; Kobara A; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
Hum Immunol; 2016 Feb; 77(2):165-71. PubMed ID: 26582002
[TBL] [Abstract][Full Text] [Related]
9. NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56.
Tarazona R; DelaRosa O; Casado JG; Torre-Cisneros J; Villanueva JL; Galiani MD; Peña J; Solana R
AIDS; 2002 Jan; 16(2):197-200. PubMed ID: 11807303
[TBL] [Abstract][Full Text] [Related]
10. SNPs rs4656317 and rs12071048 located within an enhancer in FCGR3A are in strong linkage disequilibrium with rs396991 and influence NK cell-mediated ADCC by transcriptional regulation.
Oboshi W; Watanabe T; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
Hum Immunol; 2016 Oct; 77(10):997-1003. PubMed ID: 27338556
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
Robinson JI; Md Yusof MY; Davies V; Wild D; Morgan M; Taylor JC; El-Sherbiny Y; Morris DL; Liu L; Rawstron AC; Buch MH; Plant D; Cordell HJ; Isaacs JD; Bruce IN; Emery P; Barton A; Vyse TJ; Barrett JH; Vital EM; Morgan AW; ;
EBioMedicine; 2022 Dec; 86():104343. PubMed ID: 36371989
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent CD56+ T cell responses are functionally impaired in long-term HIV-1 infection.
Fan X; Zhu L; Liang H; Xie Z; Huang X; Wang S; Shen T
Retrovirology; 2016 Nov; 13(1):76. PubMed ID: 27814766
[TBL] [Abstract][Full Text] [Related]
14. Comparing high-throughput methods to measure NK cell-mediated antibody dependent cellular cytotoxicity during HIV-infection.
Konstantinus IN; Gamieldien H; Mkhize NN; Kriek JM; Passmore JA
J Immunol Methods; 2016 Jul; 434():46-52. PubMed ID: 27094485
[TBL] [Abstract][Full Text] [Related]
15. Deficient IL-2 Produced by Activated CD56
Xie Z; Zheng J; Wang Y; Li D; Maermaer T; Li Y; Tu J; Xu Q; Liang H; Cai W; Shen T
Front Immunol; 2019; 10():1647. PubMed ID: 31379845
[No Abstract] [Full Text] [Related]
16. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
[TBL] [Abstract][Full Text] [Related]
17. HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity.
Lichtfuss GF; Meehan AC; Cheng WJ; Cameron PU; Lewin SR; Crowe SM; Jaworowski A
J Leukoc Biol; 2011 Jan; 89(1):149-58. PubMed ID: 20884651
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cellular cytotoxicity and cytokine/chemokine secretion by KHYG-1 cells stably expressing FcγRIIIA.
Kobayashi E; Motoi S; Sugiura M; Kajikawa M; Kojima S; Kohroki J; Masuho Y
Immunol Lett; 2014 Sep; 161(1):59-64. PubMed ID: 24841426
[TBL] [Abstract][Full Text] [Related]
19. CD56
Judge CJ; Kostadinova L; Sherman KE; Butt AA; Falck-Ytter Y; Funderburg NT; Landay AL; Lederman MM; Sieg SF; Sandberg JK; Anthony DD
J Leukoc Biol; 2017 Jul; 102(1):171-184. PubMed ID: 28400540
[TBL] [Abstract][Full Text] [Related]
20. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L
Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
